Skip to main content
. 2014 Aug;58(8):4612–4620. doi: 10.1128/AAC.02790-13

FIG 1.

FIG 1

Activities (changes in log10 CFU/g) of daptomycin- or linezolid-containing regimens against Enterococcus faecalis (susceptible to vancomycin, gentamicin, rifampin, daptomycin, and linezolid) (a) and Enterococcus faecium (resistant to vancomycin and rifampin; susceptible to gentamicin, daptomycin, and linezolid) (b).